• Giacomo Frosi, Alessia Biolchi, Morena Lo Sapio, Fabio Rigat, Stefanie Gilchrist, Jay Lucidarme, Jamie Findlow, Ray Borrow, Mariagrazia Pizza, Marzia Monica Giuliani, and Duccio Medini.
• Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy. Electronic address: giacomo.frosi@libero.it.
• Vaccine. 2013 Oct 9; 31 (43): 4968-74.

Background4CMenB (Bexsero), a vaccine developed against invasive meningococcal disease caused by capsular group B strains (MenB), was recently licensed for use by the European Medicines Agency. Assessment of 4CMenB strain coverage in specific epidemiologic settings is of primary importance to predict vaccination impact on the burden of disease. The Meningococcal Antigen Typing System (MATS) was developed to predict 4CMenB strain coverage, using serum bactericidal antibody assay with human complement (hSBA) data from a diverse panel of strains not representative of any specific epidemiology.ObjectiveTo experimentally validate the accuracy of MATS-based predictions against strains representative of a specific epidemiologic setting.Methods And ResultsWe used a stratified sampling method to identify a representative sample from all MenB disease isolates collected from England and Wales in 2007-2008, tested the strains in the hSBA assay with pooled sera from infant and adolescent vaccinees, and compared these results with MATS. MATS predictions and hSBA results were significantly associated (P=0.022). MATS predicted coverage of 70% (95% CI, 55-85%) was largely confirmed by 88% killing in the hSBA (95% CI, 72-95%). MATS had 78% accuracy and 96% positive predictive value against hSBA.ConclusionMATS is a conservative predictor of strain coverage by the 4CMenB vaccine in infants and adolescents.Crown Copyright © 2013. Published by Elsevier Ltd. All rights reserved.

60 keywords...

hide…